Tag: activity

FLOYD, Va. and INDEPENDENCE, Va., July 28, 2025 (GLOBE NEWSWIRE) -- Skyline Bankshares, Inc. (the “Company”) (OTC QX: SLBK) – the holding company for Skyline National Bank (the “Bank”) – announced its results of operations for the second quarter of 2025.  

NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR TO ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF SUCH JURISDICTION

LUXEMBOURG, July 26, 2025 (GLOBE NEWSWIRE) -- Bitcoin Swift (BTC3), a next-generation blockchain infrastructure protocol, is approaching the final hours of Stage 1 of its presale, offering early adopters programmable Proof-of-Yield (PoY) rewards and ecosystem access at a fixed entry price of $1.00. The project has drawn attention for launching with built-in staking incentives, AI-driven governance, and a collateral-backed stablecoin—all live from day one.

– Phase 1a clinical data in healthy participants presented for both ABI-5366 and ABI-1179, novel long-acting herpes simplex virus helicase-primase inhibitor candidates –

TORONTO, July 25, 2025 (GLOBE NEWSWIRE) -- Purpose Investments Inc. (“Purpose Investments”) announced today its decision to terminate StoneCastle Equity Growth Fund and StoneCastle Income Growth Fund (each, a “StoneCastle Fund” and together, the “StoneCastle Funds”) at the close of business on or about September 29, 2025 (the “StoneCastle Funds’ Termination Date”). Effective immediately, each StoneCastle Fund is closed to new purchases. Purpose Investments also announced its decision to terminate PK Core Fund effective as of the close of business today. PK Core Fund currently has no unitholders and is closed to new purchases.

SOUTH SAN FRANCISCO, July 25, 2025 (GLOBE NEWSWIRE) -- Recognify Life Sciences, a clinical-stage biotech company focused on developing treatments for cognitive impairment, today announced that its randomized, double-blind, placebo-controlled Phase 2b clinical trial evaluating inidascamine (formerly RL-007) in patients with cognitive impairment associated with schizophrenia (CIAS) did not meet its primary endpoint.

Company to compete for “Science Breakthrough of the Year” at Europe’s leading deep-tech summit in Berlin, Germany this November